Editor's note

This ExpertREACT article was originally published on 3 October 2008. Pipeline data and company positions described reflect the state of knowledge at that date.

115 projects: a 15-20% increase

VacZine Analytics' October 2008 review of the commercial vaccine R&D pipeline recorded approximately 115 projects, a 15-20% increase on the April 2008 figure of 97. The increase was primarily attributable to new Phase I entries in influenza and global initiative programmes (TB). Excluding biodefence, line-extensions and pandemic flu, GSK Biologicals maintained the largest vaccine pipeline closely followed by Sanofi Pasteur - which had gained the ACAM-FLU-A and ACAM-C-DIFF programmes through its July 2008 Acambis acquisition. Despite market-leading revenues, Wyeth and Merck & Co had comparatively small R&D pipelines - a structural vulnerability relative to the innovation-driven competitors.

Several paediatric combination vaccines received US approvals during the April-October 2008 period: GSK's Kinrix (DTP-IPV combination, booster in children) and Sanofi Pasteur's Pentacel (DTP-IPV-Hib combination) after a three-year approval process. In meningococcal vaccines, Novartis was pursuing an EU-focused strategy for MenACWY-CRM (11-55 years) and MenB (infants), with timely filing - particularly for MenACWY - viewed as essential to building the commercial case for infant recommendation that could follow. Novartis needed to reach market before Pfizer's rLP2086 MenB programme, which was advancing through Phase II.

Vaccine pipeline size Oct 2008
~115
Up from 97 in April 2008; a 15-20% increase driven primarily by new Phase I influenza and global initiative programme entries

Influenza R&D: a disproportionate share?

The analysis raised a provocative question: was influenza R&D investment disproportionate relative to other vaccine categories? Influenza accounted for the largest share of new Phase I entries, driven by both seasonal and pandemic programme proliferation. While the commercial rationale for further influenza pipeline investment was clear - with cell-culture, adjuvanted and universal influenza approaches all representing potentially significant value - VacZine Analytics questioned whether the concentration of industry R&D resources in influenza might be crowding out other categories with equally strong commercial and public health cases. Novel adult vaccines for nosocomial infections and meningococcal B remained chronically under-resourced relative to their potential market value.